T1	intervention 92 116	HER2 peptide GP2 vaccine
T2	eligibility 465 625	HLA-A2+, clinically disease-free, node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2 (immunohistochemistry[IHC] 1+-3+)
T3	control 673 685	GM-CSF alone
T4	intervention 655 665	GP2+GM-CSF
T5	outcome-Measure 687 714	Disease-free survival (DFS)
T6	No-of-participants 892 895	180
T7	intervention-participants 906 908	89
T8	control-participants 933 935	91
T10	intervention-value 1124 1127	88%
T11	control-value 1162 1165	81%
T13	intervention-value 1315 1318	94%
T14	control-value 1339 1342	85%
T17	intervention-value 1424 1427	94%
T18	intervention-participants 1465 1467	51
T19	control-value 1473 1476	89%
T20	control-participants 1511 1513	50
T9	outcome 1061 1119	Kaplan-Meier estimated 5-year DFS rate in the ITT analyses
T12	outcome 1255 1309	per-treatment analysis, the estimated 5-year DFS rates
T15	outcome 1364 1419	In IHC 3+/FISH+ patients, the estimated 5-year DFS rate
T16	outcome 1534 1546	ITT analyses
T21	intervention-value 1551 1555	100%
T22	control-value 1560 1563	89%
